Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2015

01-08-2015 | Breast Oncology

Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management

Authors: Laura E. G. Warren, MD, EdM, Hao Guo, MS, Meredith M. Regan, ScD, Faina Nakhlis, MD, Eren D. Yeh, MD, Heather A. Jacene, MD, Judi Hirshfield-Bartek, RN, Beth A. Overmoyer, MD, Jennifer R. Bellon, MD

Published in: Annals of Surgical Oncology | Issue 8/2015

Login to get access

Abstract

Background

Inflammatory breast cancer (IBC) is a rare and aggressive subtype. This study analyzes the patterns of failure in patients with IBC treated at our institution.

Methods

We retrospectively analyzed the records of 227 women with IBC presenting between 1997 and 2011. Survival analysis was used to calculate overall survival (OS) and disease-free survival. Competing risk analysis was used to calculate locoregional recurrence (LRR).

Results

A total of 173 patients had locoregional-only disease at presentation (non-MET). Median follow-up in the surviving patients was 3.3 years. Overall, 132 (76.3 %) patients received trimodality therapy with chemotherapy, surgery, and radiotherapy. Three-year OS was 73.1 % [95 % confidence interval (CI) 64.9–82.4]. Cumulative LRR was 10.1, 16.9, and 21.3 % at 1, 2, and 3 years, respectively. No variable was significantly associated with LRR. Fifty-four patients had metastatic disease at presentation (MET). Median follow-up in the surviving patients was 2.6 years. Three-year OS was 44.3 % (95 % CI 31.4–62.5). Twenty-four (44.4 %) patients received non-palliative local therapy (radiotherapy and/or surgery). For these patients, median OS after local therapy was 2 years. Excluding six patients who received local therapy for symptom palliation, the crude incidence of locoregional progression or recurrence (LRPR) was 17 % (4/24) for those who received local therapy compared with 57 % (13/23) for those who did not.

Conclusions

For non-MET patients, LRR remains a problem despite trimodality therapy. More aggressive treatment is warranted. For MET patients, nearly 60 % have LRPR with systemic therapy alone. Local therapy should be considered in the setting of metastatic disease to prevent potential morbidity of progressive local disease.
Literature
1.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer staging manual. 7th ed. Chicago (IL): Springer; 2011.
2.
Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23.PubMedCentralPubMedCrossRef
3.
Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007;110(7):1436–44.PubMedCrossRef
4.
Anderson BWF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21(12):2254–9.PubMedCrossRef
5.
Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival. The Surveillance, Epidemiology, and End Results Program of the National Cancer. Cancer. 1998;82(12):2366–72.PubMedCrossRef
6.
Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007;18(6):1021–9.PubMedCrossRef
7.
Kleer CG, Zhang Y, Pan Q, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 2004;6(2):R110–5.PubMedCentralPubMedCrossRef
8.
Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002;62(2):560–6.PubMed
9.
Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61(13):5231–41.PubMed
10.
Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol. 2002;20(17):3637–43.PubMedCrossRef
11.
Huang EH, Tucker SL, Strom EA, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(2):351–7.PubMedCrossRef
12.
Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol. 2000;47(5):1191–200.CrossRef
13.
Damast S, Ho AY, Montgomery L, et al. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. Int J Radiat Oncol Biol Phys. 2010;77(4):1105–12.PubMedCrossRef
14.
Rehman S, Reddy CA, Tendulkar RD. Modern outcomes of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2012;84(3):619–24.PubMedCrossRef
15.
Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2014;29(8):1014–21.CrossRef
16.
Brito RA, Valero V, Buzdar AU, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001;19(3):628–33.PubMed
17.
Harris EER, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55(5):1200–8.PubMedCrossRef
18.
Bristol IJ, Woodward WA, Strom EA, Cristofanilli M. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol. 2008;72(2):474–84.CrossRef
19.
Liauw SL, Benda RK, Morris CG, Mendenhall NP. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer. 2004;100(5):920–8.PubMedCrossRef
20.
Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994;30A(7):921–7.PubMedCrossRef
21.
Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321–9.PubMedCrossRef
22.
Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005;23(9):1941–50.PubMedCrossRef
23.
Bauer RL, Busch E, Levine E, Edge SB. Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy. Ann Surg Oncol. 1995;2(4):288–94.PubMedCrossRef
24.
Takiar V, Akay CL, Stauder MC, et al. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus. 2014;3:166.PubMedCentralPubMedCrossRef
25.
Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014;120(9):1319–28.PubMedCentralPubMedCrossRef
26.
27.
Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer. 2008;113(8):2011–9.PubMedCrossRef
28.
Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24(18):2743–9.PubMedCrossRef
29.
Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14(12):3345–51.PubMedCrossRef
30.
Henderson MA, McBride CM. Secondary inflammatory breast cancer: treatment options. South Med J. 1988;81(12):1512–7.PubMedCrossRef
31.
McBride CM, Hortobagyi GN. Primary inflammatory carcinoma of the female breast: staging and treatment possibilities. Surgery. 1985;98(4):792–8.PubMed
32.
Piera JM, Alonso MC, Ojeda MB, Biete A. Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol. 1986;7(3):199–204.PubMedCrossRef
33.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81.CrossRef
34.
Greenwood M. The errors of sampling of the survivorship tables. Reports Public Heal Stat Subj. 1926;33(1):26.
35.
Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–54.CrossRef
36.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.CrossRef
37.
38.
Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014;32(19):2018–24.PubMedCentralPubMedCrossRef
39.
Dawood S, Ueno NT, Valero V, et al. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol. 2012;23(4):870–5.PubMedCrossRef
Metadata
Title
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management
Authors
Laura E. G. Warren, MD, EdM
Hao Guo, MS
Meredith M. Regan, ScD
Faina Nakhlis, MD
Eren D. Yeh, MD
Heather A. Jacene, MD
Judi Hirshfield-Bartek, RN
Beth A. Overmoyer, MD
Jennifer R. Bellon, MD
Publication date
01-08-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 8/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4469-4

Other articles of this Issue 8/2015

Annals of Surgical Oncology 8/2015 Go to the issue

Breast Oncology

Long-Term Comparison of Aesthetical Outcomes After Oncoplastic Surgery and Lumpectomy in Breast Cancer Patients

Healthcare Policy and Outcomes

Pancreatic Resection Results in a Statewide Surgical Collaborative

Thoracic Oncology

Clinical Significance of SIP1 and E-cadherin in Patients with Esophageal Squamous Cell Carcinoma

Gynecologic Oncology

Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis

Gastrointestinal Oncology

Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer

Breast Oncology

A Patient-Centered Approach to Wait Times in the Surgical Management of Breast Cancer in the Province of Ontario